Motor Neurone Disease: Testing a potential new treatment for ALS - Wesley Research Institute
Wesley Research Institute
Donate
Now

The main objective of this current study is to determine how safe and well-tolerated PMX-205 is in individuals diagnosed with ALS, when given as a single dose. It’s hoped the treatment will improve survival and quality of life.

Research Objectives

Status

Completed

Recruitment

Open

Patient Group

Amyotrophic Lateral Sclerosis (ALS)

Phase

1b

Study type

Industry Sponsored
Sponsors: Alsonex Pty Ltd

Lead investigators

  • A/Prof Robert Henderson

Clinical Trial Coordinator

  • Jacqui Langton

Technical title

An open-label, phase 1b study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of PMX205 in patients with amyotrophic lateral sclerosis.

About this research project

This research project is testing a potential new treatment for ALS, called PMX-205. PMX-205 is hoped to improve survival and quality of life. Despite the current advances in medical therapy, there is currently no known cure for Amyotrophic lateral sclerosis (ALS). The management of ALS is predominantly about providing symptomatic relief, improving quality of life, extending survival time and/or slowing disease progression.

Alsonex Pty Ltd is developing a new drug, PMX-205, that works by targeting the inflammatory pathway that is believed to contribute to the damage in nerve cells. This inflammation could be a part of the primary cause of the disease.

The main objective of this current study is to determine how safe and well-tolerated PMX-205 is in individuals diagnosed with ALS, when given as a single dose.

The study also aims to study how PMX-205 is absorbed into the bloodstream and cerebrospinal fluid (CSF, the clear fluid around the brain and spinal cord) in individuals diagnosed with ALS and the effect that PMX-205 has on participants’ immune cells (different types of white blood cells).

Latest News

Lung Cancer METASPATIAL Study awarded $1 million by the Australian Government

We’re delighted to announce that Dr Arutha Kulasinghe is leading the Lung Cancer METASPATIAL Study that has been awarded nearly $1m by the Australian Government. The project is supported by the Wesley Research Institute and the University of Queensland. The METASPATIAL Study will be undertaken over the next 4 years at Wesley Research Institute’s new Queensland Spatial Biology Centre (QSBC).

Lung Cancer Survivor Michel Itel an advocate for Spatial Mapping of Digital Pathology

As a patient with a specific EGFR positive mutation, Michel benefited from targeted therapy, an approach that the new Queensland Spatial Biology Centre (QSBC) aims to enhance for future patients.
Amanda

Amanda’s Story

Flashback to the middle of 2019, it was just like any other normal day at work for Amanda, until she noticed a lump in her groin.
1 2 3 8
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram